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Abstract
 
Currently most attempts at cancer immunotherapy involve the generation of CD8
 
 
 
 cytotoxic
T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been
immunoselected to evade recognition by CTLs and thus alternative approaches to cancer
immunotherapy are urgently needed. Here we demonstrate that CD4
 
 
 
 T cells that recognize a
secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2
cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma.
Clearance of lung metastases by the Th2 cells was found to be totally dependent on the
eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal
transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the
tumors inducing tumor regression. In contrast, tumor-specific CD4
 
 
 
 Th1 cells, that recruited
macrophages into the tumors, had no effect on tumor growth. This work provides the basis for
a new approach to adoptive T cell immunotherapy of cancer.
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Introduction
 
There is ample evidence that many tumors express antigens
that can be recognized by the adaptive immune system (1)
and potentially can be used to induce an antitumor immune
response. Until now most cancer immunotherapy studies
have focused on the generation of CD8
 
 
 
 CTLs that recognize
tumor antigens, in association with MHC class I molecules, on
tumor cells. With mounting evidence that many tumors have
been immunoselected to evade recognition by CTLs (2)
alternative approaches to cancer immunotherapy need to
be investigated. In this context, the induction of tumor-
specific CD4
 
 
 
 T cells has been largely ignored, except when
optimum activation and development of CD8
 
 
 
 CTLs is
thought to depend on help from CD4
 
 
 
 T cells (3, 4).
Based on their profile of secreted cytokines, CD4
 
 
 
 T cells
have been frequently subdivided into two subpopulations,
Th1 and Th2, with the Th1 cells predominantly producing
IL-2 and IFN-
 
 
 
 and the Th2 cells preferentially secreting
IL-4, IL-5, and IL-10 (5). It is generally thought, however,
that only Th1 cells provide help to CD8
 
 
 
 CTLs, the Th2
cells regulating humoral immune responses (5). On the other
hand, there are a number of reports suggesting that both
CD4
 
 
 
 Th1 and Th2 cells may act independently of CD8
 
 
 
CTLs and play a direct role in the elimination of tumors
(6–8). In these cases tumor eradication may be mediated by
tumoricidal myeloid cells recruited into the tumors (6, 9,
10) or by anti-angiogenic cytokines, such as IL-4, secreted
by CD4
 
 
 
 T cells (11).
To elucidate the direct antitumor activity of Th1 and
Th2 cells, particularly against tumors resistant to CTL lysis,
we exploited a highly metastatic and CTL-resistant tumor
cell line (B16 mouse melanoma). This line was transfected
with the chicken protein, OVA, to yield the B16-OVA
melanoma line, the OVA acting as a surrogate secreted
tumor-specific antigen. Polyclonal populations of OVA-
specific CD4
 
 
 
 T cells, that were polarized to produce
either Th1 or Th2 cytokines, were then examined for
their ability to eliminate established metastases of the
B16-OVA melanoma. Here we report that OVA-specific
Th2 cells, but not Th1 cells, are capable of clearing metastases
produced by the B16-OVA melanoma, with tumor
clearance being dependent on the eosinophil chemokine,
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eotaxin, the IL-4 receptor/signal transducer and activator of
transcription 6 (STAT6) signaling pathway and degranulating
eosinophils within the tumors.
 
Materials and Methods
 
Mice and Tumor Cell Lines.
 
C57BL/6 mice and various gene
knockout mice on a C57BL/6 background were used between
6–8 wk of age. All animal experimental protocols were approved
by the Australian National University Animal Experimentation
Ethics Committee. The B16-F1 melanoma cell line was transfected
with OVA as reported previously (12), to yield the B16-OVA line.
 
OVA-specific T Cell Populations.
 
OVA specific CD4
 
 
 
 Th1,
Thi and Th2 cells were generated as described previously (13).
Briefly, C57BL6 mice were primed with OVA in alum and 6 d
later the splenocytes from the immunized mice cultured for 4 d
with OVA alone (Thi cells) or in combination with IL-12 and a
neutralizing anti–IL-4 mAb to generate Th1 cells or IL-4 and a
neutralizing anti–IFN-
 
 
 
 mAb to generate Th2 cells. CD4
 
 
 
 T
cells, purified by magnetic beads, were then transferred into tu-
mor bearing mice or restimulated in vitro with OVA to confirm
the cytokine profile of the CD4
 
 
 
 T cells.
 
Tumor Metastasis Assays.
 
B16 and B16-OVA melanoma cells
(3 
 
 
 
 10
 
5
 
) were injected intravenously into recipient mice. After
7 d, when lung metastases were macroscopically visible (typically
 
 
 
150 metastases/mouse), Th1, Thi, or Th2 cells (2 
 
 
 
 10
 
7
 
) were
transferred intravenously into the tumor-bearing mice. 14 d after
tumor challenge, mice received a second intravenous injection of
T cells (2 
 
 
 
 10
 
7
 
). The antitumor activity mediated by the trans-
ferred cells was determined by counting the number of lung me-
tastases 18–20 d after tumor challenge. Tumor-bearing lungs
were fixed in 10% phosphate-buffered formalin 72 h after the first
T cell transfer, sectioned, and stained with Carbol’s chromo-
trope-hematoxylin for identification of eosinophils. Fixed lung
sections were also immunostained either with an anti-major basic
protein (MBP) antibody (14) to identify eosinophils or with the
F4/80 mAb to identify intratumoral macrophages.
 
Cytotoxicity Assays.
 
Eosinophil cytotoxicity was determined
by a 6-h 
 
51
 
Cr-release assay using B16-OVA melanoma cells as tar-
get cells. Eosinophils were isolated from the peritoneal cavity of
naive IL-5 transgenic C57Bl/6 mice by sorting, based on forward
and side light-scatter, using a Becton Dickinson FACStar
 
Plus™
 
 flow
cytometer with purity of the sorted eosinophils being 
 
 
 
98%. Eo-
sinophils were lysed by freeze-thawing three times and the eosino-
phil lysates then incubated with B16-OVA melanoma targets.
 
Results
 
CD4
 
 
 
 Th2 Cells, but Not Th1 Cells, Are Able to Eradicate
Established Melanoma Metastases.
 
Initial studies demon-
strated, by ELISA, that the B16-OVA melanoma secreted
low levels of OVA, confluent cultures only containing
 
 
 
100 ng/ml in the culture medium. The B16-OVA cells
also exhibited comparable metastatic activity to the B16
parent line and were largely resistant to lysis by OVA-spe-
cific CD8
 
 
 
 CTLs both in vitro and in vivo, except when
very high avidity CTLs were used (M. Estcourt and I.
Ramshaw, personal communication). Serological studies
also revealed that the B16-OVA cells expressed no detect-
able class I or class II MHC antigens on their surface (un-
published data). Polyclonal populations of OVA-specific
CD4
 
 
 
 Th1 and Th2 cells were then prepared by culturing
splenocytes from OVA immunized mice with OVA in the
presence of either IL-12 and anti–IL-4 (to generate OVA-
specific Th1 cells) or IL-4 and anti–IFN-
 
 
 
 (to generate
OVA-specific Th2 cells; reference 13). Culturing the sple-
nocytes in OVA alone resulted in an intermediate Th1/Th2
phenotype (termed OVA-specific Thi cells). To confirm
the Th phenotype of the different T cell populations, the
cytokine profile of the different CD4
 
 
 
 T populations after
OVA restimulation in vitro was assessed. As expected, the
OVA-specific Th1 cells produced no detectable IL-4 and
IL-5 but high levels of IFN-
 
 
 
 (Fig. 1 a) whereas the OVA-
specific Th2 population secreted IL-4 and IL-5 but no de-
tectable IFN-
 
 
 
 (Fig. 1 c). By contrast, the Thi population
produced both Th1 and Th2 cytokines (Fig. 1 b). IL-13 and
TNF
 
 
 
 were secreted by all three OVA-specific T cell pop-
ulations (Fig. 1, a–c), although the Th1 cells released sub-
stantially less IL-13 than the Thi and Th2 populations.
Figure 1. Cytokine production by different polyclonal populations of
OVA-specific CD4  T cells. (a) Th1, (b) Thi, and (c) Th2 populations of
T cells. Cytokine production (pg/ml) was measured by ELISA in culture
supernatants following OVA restimulation of the different T cell populations
for 48 h. Error bars represent SEM.T
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To test the antitumor activity of the Th1 and Th2 cells,
syngeneic C57BL/6 mice were injected intravenously with
3 
 
 
 
 10
 
5
 
 B16-OVA tumor cells and 7 d later, when 
 
 
 
100 tu-
mor metastases were macroscopically visible in the lungs of
each mouse, 2 
 
 
 
 10
 
7
 
 OVA-specific CD4
 
 
 
 T cells were
adoptively transferred into each tumor bearing animal. A sec-
ond dose of OVA-specific CD4
 
 
 
 T cells was administered
14 d after tumor cell injection and lung metastases quantified
18–20 d after tumor challenge. Compared with untreated
control animals, the OVA-specific Th1 cells had no effect on
tumor growth (Fig. 2, a and c). By contrast, both the OVA-
specific Thi and Th2 populations significantly reduced the
number of surface lung metastases, with the Th2 cells reduc-
ing metastases by 
 
 
 
90%. Furthermore, the lung metastases
that persisted in the Th2 cell–treated animals were much
smaller than in the other treatment groups (Fig. 2 a). Indeed,
histological examination of lungs from Th2 cell recipients re-
vealed that micro-metastases were only detectable immedi-
ately beneath the lung surface, with the remainder of the
lung tissue being totally devoid of tumor cells. A single dose
of OVA-specific Th2 cells reduced the number of surface
lung metastases by 
 
 
 
70–80% whereas a second dose of Th2
cells resulted in 
 
 
 
90% reduction, thus in all subsequent ex-
periments two doses of CD4
 
 
 
 T cells were administered.
After multiple passages in vitro the B16-OVA melanoma
line gained the ability to metastasize to most abdominal or-
gans (i.e., liver, stomach, duodenum, small intestine, colon,
spleen) after intravenous injection. When OVA-specific Th2
cells were transferred to mice receiving multiply passaged
B16-OVA cells, not only clearance of tumors from the lungs
resulted but a dramatic inhibition of tumor growth in ab-
dominal organs occurred (Fig. 2 b), indicating that the anti-
tumor effect of the OVA-specific Th2 cells is not restricted
to the pulmonary compartment. In addition, the antitumor
activity of the Th2 cells was OVA-specific, as the OVA-spe-
cific Th2 cells had no effect on the lung metastases of the
parent B16 melanoma cell line (Fig. 2 c).
 
Eradication of Melanoma Metastases by CD4
 
 
 
 Th2 Cells Is
Associated with an Influx of Eosinophils into the Tumors.
 
His-
tological examination of B16-OVA lung tumors 72 h after
the first injection of the different CD4
 
 
 
 T cell populations
revealed that there were considerable numbers of eosinophils
in the tumors of mice receiving OVA-specific Th2 (Fig. 3 a)
and Thi cells, i.e., approximately a 30-fold increase above
the background eosinophil content of tumors in mice re-
ceiving no CD4
 
 
 
 T cells (Fig. 3, c and g). By contrast, in
mice receiving OVA-specific Th1 cells only background
levels of eosinophils were detected in the lung tumors (Fig.
3, b and g). The influx of eosinophils into tumors was OVA-
specific as the Th2 cells were unable to recruit eosinophils
into the OVA-deficient tumors produced by the parent B16
melanoma (1.9 
 
 
 
 0.3 eosinophils/high power field (HPF)
were detected in the B16 tumors of Th2 cell recipients com-
pared with 1.3 
 
 
 
 0.2 eosinophils/HPF in the B16 tumors of
control mice). Also, when OVA-specific Th2 cells were la-
beled with the intracellular fluorescent dye CFSE (15) they
were found, by immunofluorescence microscopy, to have
localized in the B16-OVA lung tumors (unpublished data).
Figure 2. Adoptively transferred populations of OVA-specific
CD4  Thi and Th2 cells, but not Th1 cells, inhibit the growth of lung
metastases produced by an OVA-transfected B16 melanoma (B16-
OVA). (a) Macroscopic view of the lungs from an untreated (Control)
mouse or mice receiving OVA-specific Th1, Thi, or Th2 cells. (b)
Visceral melanoma metastases in the organs of an untreated (Control)
mouse and a mouse receiving OVA-specific Th2 cells. (c) Quantification
of clearance of melanoma lung metastases, relative to the untreated
control, by the different OVA-specific CD4  T cell populations. Un-
treated control mice usually contained 100–200 melanoma metastases in
their lungs. Error bars represent SEM (n   6–7 mice).T
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The presence of eosinophils in the tumors of mice re-
ceiving OVA-specific Th2 cells, but not in the tumors of
either control or Th1 cell–treated animals, was confirmed
immunohistochemically by staining for the eosinophil
granule protein, MBP (Fig. 3, d–f). In the case of macro-
phages the converse was true, as we observed an influx of
macrophages approximately fourfold above background in
the tumors of mice receiving OVA-specific Th1 cells (P 
 
 
 
0.0004 compared with controls), with macrophage num-
bers barely increasing above background levels in tumors
from Th2-treated animals (Fig. 3 g). Thus, Th1 tumor-spe-
cific immunity, in contrast to Th2 immunity, had no effect
on tumor growth, despite considerable numbers of macro-
phages becoming localized in the tumors.
 
Elimination of Melanoma Metastases by CD4
 
 
 
 Th2 Cells Is
Dependent on Eotaxin and STAT6.
 
A number of gene
knockout mice were used to further probe the molecular
and cellular basis of the inhibition of tumor growth by Th2
cells. OVA-specific Th2 cells were capable of clearing B16-
OVA tumor metastases in RAG1
 
 
 
/
 
 
 
 mice, the Th2 cells
being almost as effective as in wild-type C57BL/6 mice
(Fig. 4 a). Eosinophil influx into the tumors was also un-
changed in RAG1
 
 
 
/
 
 
 
 mice (Fig. 4 b). As RAG1
 
 
 
/
 
 
 
 mice
lack lymphocytes these findings substantiate that Th2 cell–
mediated antitumor immunity occurs independent of re-
cipient T cells, NKT cells, and B cells. In contrast, the Th2
cells were substantially less effective at reducing lung me-
tastases in STAT6–deficient (STAT6
 
 
 
/
 
 
 
) mice than in
wild-type recipients (P 
 
  
 
0.001), although there was still
significant inhibition of tumor growth in the STAT6-defi-
cient mice (P
 
 
 
0.02; Fig. 4 a). STAT6 plays an essential
role in signaling via the IL-4 receptor (IL-4R; reference
16), with the IL-4R–STAT6 pathway inducing secretion
of the eosinophil chemokine, eotaxin, by epithelial cells
(17). Interestingly, STAT6 deficiency also resulted in only
a partial reduction in the eosinophil content of tumors in
the Th2 recipient mice (Fig. 4 b), indicative of a STAT6-
independent pathway of eosinophil recruitment. Such a
pathway has been described for eotaxin induction in hu-
man epithelial cells (18). Conversely, IL-5, a cytokine
known to regulate eosinophil expansion and recruitment
from the bone marrow into the circulation (19), played no
Figure 3. Clearance of B16-OVA lung metastases by OVA-specific CD4  T cells correlates with the influx of eosinophils, but not macrophages,
into tumors. Eosinophil staining (a–c) and immunohistochemical detection of eosinophil MBP (d–f) in sections of lung tumors ( 400) from a
control mouse or from mice 72 h after receiving OVA-specific Th2 or Th1 cells. (g) Number of either eosinophils (Eos), detected by staining
with Carbol’s chromotrope-hematoxylin, or macrophages (Mac), detected with the F4/80 mAb/tumor HPF (  SEM) in untreated (control) mice
or mice receiving Th2 or Th1 cells.T
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role in tumor clearance as IL-5–deficient Th2 cells, when
transferred to IL-5
 
 
 
/
 
 
 
 recipients, were unimpaired in their
ability to eliminate lung metastases or recruit eosinophils
into the tumors (Fig. 4, a and b). As IL-5 is produced by
Th2 cells (Fig. 1 c), Th2 cells generated in IL-5
 
 
 
/
 
 
 
 mice
were used in these experiments. The critical role played by
eotaxin in Th2-mediated tumor regression was evident in
eotaxin-deficient mice which failed to clear tumor me-
tastases after the administration of OVA-specific IL-5
 
 
 
/
 
 
 
Th2 cells (Fig. 4 a). As would be expected, eotaxin defi-
ciency was also associated with low level entry of eosino-
phils into the tumors (Fig. 4 b). As with the eotaxin-defi-
cient recipients, IL-5
 
 
 
/
 
 
 
 Th2 cells were also unable to
eliminate B16-OVA tumors in mice deficient in both IL-5
and eotaxin, with eosinophil entry into the tumors being at
background levels (Fig. 4, a and b). Previous studies have
shown that Th2 cytokines can induce eotaxin production
by lung epithelial cells (17, 18). As little or no eosinophil
recruitment was observed in tumors in eotaxin-deficient
 
recipients, this indicates that the tumor cells themselves are
not eotaxin producers.
 
Detection of Degranulating Eosinophils in Regressing Tumors.
 
Immunohistochemical studies provided evidence for degranu-
lating eosinophils in the tumors of mice receiving OVA-spe-
cific Th2 cells, with eosinophil MBP being detected free of
eosinophils in the tumors (Fig. 5 a). Thus it appears likely that
cellular toxins, such as MBP, released from eosinophil granules
may mediate tumor destruction. When eosinophils were incu-
bated with tumor cells in vitro no lysis of the tumor cells was
observed, although eosinophil lysates were found to be cyto-
toxic (Fig. 5 b), supporting the view that eosinophil granule
proteins are tumoricidal. Addition of cytokine containing su-
pernatants from OVA stimulated Th1, Thi, or Th2 cells (Fig.
1), with or without eotaxin, to the eosinophil–tumor cell
mixture also resulted in no detectable lysis of the tumor cells
(unpublished data). Thus, it appears that in vivo factors pro-
vided by the tumor microenvironment facilitate eosinophil
degranulation and destruction of the tumor cells.
Figure 4. Clearance of B16-
OVA lung metastases and re-
cruitment of eosinophils into
tumors by OVA-specific Th2
cells is independent of recipient
lymphocytes and IL-5 but is
STAT6 and eotaxin dependent.
Ability of OVA-specific Th2 cells,
either WT or IL-5 deficient, (a) to
inhibit lung tumor metastases or
(b) to induce an eosinophil influx
into the lung tumors of various
gene knockout mice. Asterisks
refer to significant difference
between treatments and WT
controls with *P   0.05   0.01,
**P     0.01   0.001,  ***P   
0.001   0.0001, and ns, not sig-
nificant.
Figure 5. Degranulating eosinophils can be detected in B16-OVA
lung metastases and eosinophil lysates are cytotoxic for B16-OVA tumor
cells. (a) Immunohistochemical detection of eosinophil MBP in sections
( 1,000) of a B16-OVA lung tumor from a mouse 72 h after receiving
OVA-specific Th2 cells. Arrows indicate the presence of MBP staining material free of eosinophils, indicative of eosinophil degranulation, with
intact eosinophils staining for MBP being highlighted with white asterisks. Staining representative of  10 tumor sections. (b) Ability of eosinophils
or eosinophil lysates, at different effector to target cell ratios, to lyse 51Cr-labeled B16-OVA tumor cells.T
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Discussion
This study indicates that tumor-specific CD4  T cells
with a cytokine profile characteristic of Th2 cells can very
effectively eliminate lung and visceral tumor metastases that
are resistant to eradication by tumor-specific CTLs. In fact,
the study implies that tumor-specific Th2 cells are much
more effective against highly metastatic solid tumors than is
generally realized. Also, based on histological analyses and
the use of a range of gene knockout mice, compelling evi-
dence was obtained that tumor elimination by Th2 cells is
dependent upon an influx of eosinophils into the tumors.
Of critical importance here was the failure of the Th2 cells
to clear lung metastases in eotaxin-deficient recipient mice,
the chemokine eotaxin being reported previously to medi-
ate the recruitment of eosinophils into tissues (20). Further-
more, the reduced capacity of Th2 cells to eliminate tu-
mors in STAT6-deficient mice is consistent with eotaxin
playing an essential role in tumor clearance as eotaxin pro-
duction by lung epithelial cells is largely dependent on sig-
naling by the IL-4R–STAT6 pathway (21, 22). In contrast,
recipient CD8  CTLs, CD4  T cells, NKT cells, and B
lymphocytes are unlikely to participate in tumor elimina-
tion as the Th2 cells were active in RAG1-deficient recipi-
ents. Based on our data it appears likely that tumor cell
eradication induced by Th2 cells is mediated by cytotoxic
proteins, such as MBP, released by degranulating eosino-
phils, although we were unable to identify in vitro the fac-
tors that induce eosinophil degranulation. It is conceivable,
however, that the eosinophils may also be tumoricidal via
other mechanisms such as superoxide and nitric oxide pro-
duction (6).
An intriguing feature of this study is that tumor-specific
Th1 cells were unable to inhibit tumor growth despite recruit-
ing macrophages into the tumors. This apparent paradox may
be explained by the observation that, rather than being tumor-
icidal, tumor-infiltrating macrophages are often pro-angio-
genic and favor tumor growth (23, 24). In fact, tumor-infil-
trating macrophages are associated with a poor prognosis in
melanoma and breast cancer patients (24, 25). Nevertheless,
there are reports that in certain situations CD4  Th1 cells can
directly eradicate tumors (6, 7). The reason for this discrep-
ancy with our results is probably related to the tumor models
employed. For example, in one case CD4  T cells were ex-
amined for their ability to eliminate tumor cells expressing
MHC class II molecules (7), whereas in another instance the
tumor-specific CD4  Th1 cells were induced by irradiated,
GM-CSF–expressing, tumor cells (6).
There are a number of earlier reports suggesting that eosi-
nophils may be capable of eliminating tumors, with the cur-
rent study providing definitive evidence that eosinophils are
involved in tumor clearance. Tumor cells transfected with IL-
4 grow poorly in recipient animals, the poor tumor growth
appearing to be associated with an IL-4–induced influx of
eosinophils (9, 10), although recent studies suggest that IL-4
can also be anti-angiogenic (11). Similarly, the direct antitu-
mor activity of CD4  T cells appears to correlate with tumors
being infiltrated with eosinophils (6).
A common feature of many spontaneously occurring
tumors is that they evade CTL elimination by loss of
MHC molecule expression (2), as is the case for the B16
melanoma used in this study. By contrast, as Th2 cells can
respond to secreted tumor antigens presented, in associa-
tion with MHC class II molecules, by bystander antigen-
presenting cells, and recruit eosinophils into the tumor
that are nonspecifically tumoricidal via soluble factors, this
type of immune attack may be less susceptible to immune
evasion. Certainly, unlike CTLs, this form of tumor im-
munity would still be effective against single cells arising
within a tumor that lack MHC molecules or the antigen
against which the antitumor immune response is directed,
the cytotoxic proteins released by degranulating eosino-
phils killing such cells as “innocent” bystanders. By focus-
ing the immune response on tumor antigens that are es-
sential for cell survival (26), the chances of immune
escape would be reduced even further.
Thus, it can be proposed that the induction of Th2 im-
munity to secreted tumor-specific antigens, and resultant
eosinophil-induced tumor regression, represents a viable
approach to cancer immunotherapy. Perhaps the success of
such an approach is to be expected, as degranulating eosi-
nophils in the lungs of chronic asthmatics are known to
cause extensive tissue destruction (27). On the other hand,
we observed that Th2 cells rapidly eliminated lung me-
tastases with there being no histological evidence of lung
damage or persistent inflammation after tumor clearance.
This finding raises the intriguing possibility that tumor-spe-
cific Th2 immunity could be continually eradicating mi-
cro-metastases with there being no lasting histological
changes to indicate that this has actually occurred.
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